CorMedix Inc. CRMD
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
3.07
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $311.7M | $163.1M | $275.7M | $172.8M | $405.3M |
| 2024 | $43.5M | -$17.9M | $40.3M | -$50.7M | $84.7M |
| 2023 | — | -$46.3M | — | -$38.7M | $70.1M |
| 2022 | $65,408 | -$29.7M | $61,674 | -$24.6M | $55.1M |
| 2021 | $190,936 | -$28.2M | $41,998 | -$22.6M | $62.8M |
| 2020 | $239,231 | -$22.0M | $34,385 | -$22.1M | $44.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Zelnick Kaufman Beth | Chief Legal Officer | 2026-02-04 | Grant | 36,006 | — |
| Hurlburt Elizabeth | Chief Operating Officer | 2026-02-04 | Grant | 36,006 | — |
| Todisco Joseph | Chief Executive Officer | 2026-02-04 | Grant | 77,156 | — |
| Lefkowitz Steven W | director | 2026-01-26 | Grant | 30,453 | — |
| Kaplan Myron | director | 2026-01-26 | Grant | 30,453 | — |
| Dillione Janet | director | 2026-01-26 | Grant | 30,453 | — |
| Zelnick Kaufman Beth | Chief Legal Officer | 2026-01-23 | Tax withheld | 8,803 | $7.27 |
| Hurlburt Elizabeth | Chief Operating Officer | 2026-01-23 | Grant | 93,010 | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.07 (safe)
- Working capital / assets 0.233
- Retained earnings / assets -0.214
- EBIT / assets 0.182
- Equity / liabilities 0.963
Source: SEC EDGAR filings · CIK 0001410098 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.